Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vestcor Inc

Vestcor Inc lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 58.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,480 shares of the biopharmaceutical company’s stock after selling 33,107 shares during the quarter. Vestcor Inc’s holdings in Catalyst Pharmaceuticals were worth $548,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Rothschild Investment LLC lifted its position in shares of Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,520 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $40,000. Clearstead Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares in the last quarter. Finally, Financial Life Planners acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $42,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Finally, Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.34 on Wednesday. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $32.56. The company has a market cap of $3.84 billion, a PE ratio of 18.01, a P/E/G ratio of 0.95 and a beta of 0.74. The business has a 50-day simple moving average of $28.74 and a 200-day simple moving average of $25.47.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).